Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
| ▸ | PTPRF | P10586 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GRM6 | O15303 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL109178 | 0.86 | TSHR (0.50) | TDP1MEN1KMT2AADRA1AADRA1B | |
| SCHEMBL30111657 | 0.86 | TSHR (0.50) | TDP1MEN1KMT2AADRA1AADRA1B | |
| SCHEMBL28561247 | 0.84 | GRM6 (0.38) | PTPN2PTPN1PTPRFMEN1KMT2A | |
| Hydrogen Peroxide SCHEMBL29048859 | 0.84 | TSHR (0.48) | TDP1MEN1KMT2AADRA1AADRA1B | |
| SCHEMBL21258127 | 0.81 | TSHR (0.58) | PTPN2PTPN1PTPRFTDP1MEN1 | |
| SCHEMBL18605959 | 0.81 | POLB (0.37) | KMT2AADRA1AADRA1BALDH1A1HSD17B10 | |
| SCHEMBL31664478 | 0.81 | POLB (0.37) | KMT2AADRA1AADRA1BALDH1A1HSD17B10 | |
| Ethane SCHEMBL4639855 | 0.80 | GRM6 (0.36) | TDP1MEN1KMT2AADRA1AADRA1B | |
| SCHEMBL27966648 | 0.79 | PTPN2 (0.40) | PTPN2PTPN1PTPRFTDP1MEN1 | |
| SCHEMBL23559560 | 0.79 | PTPN2 (0.40) | PTPN2PTPN1PTPRFTDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114163369-A | Preparation method of sulfur/oxygen ester group-containing aromatic hydrocarbon compound | 武汉工程大学 | 2022-03-11 | — | — | CN | claimed |
| US-20260130925-A1 | METHODS FOR TREATING CANCER | GENESIS MOLECULAR AI INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4705281-A1 | COMPOUNDS FOR TREATING CANCER | Genesis Molecular AI, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4602031-A1 | METHODS FOR TREATING CANCER | Genesis Therapeutics, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| WO-2025045106-A1 | PI3Kα INHIBITOR AND USE THEREOF | 郑州同源康医药有限公司 | 2025-03-06 | — | — | WO | disclosed |
| EP-4499630-A1 | BCL-XL INHIBITORS | BeiGene, Ltd. (KY) | 2025-02-05 | — | — | EP | disclosed |
| US-20250034128-A1 | BCL-XL INHIBITORS | BEIGENE, LTD. (KY) | 2025-01-30 | — | — | US | disclosed |
| CN-118974033-A | Bcl-xL inhibitors | 百济神州有限公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2024229121-A1 | COMPOUNDS FOR TREATING CANCER | GENESIS THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| CN-118027018-A | Tetrahydrocyclopentyl [ c ] pyrrole methyl ketone derivative, preparation method and application thereof | 江苏恩华药业股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-0505098-A1 | Imidazole derivatives bearing acidic functional groups as angiotensin II antagonists | MERCK & CO. INC. (US) | 1992-09-23 | — | — | EP | disclosed |
| EP-0490587-A1 | Substituted pyrazolopyrimidines and imidazopyridazines as angiotensin II antagonists | MERCK & CO. INC. (US) | 1992-06-17 | — | — | EP | disclosed |
| US-5102880-A | Biphenyl imidazotriazine derivatives; Hypotensive and cardiotonic agents | MERCK & CO., INC. (US) | 1992-04-07 | — | — | US | disclosed |
| US-5100897-A | Hypotensive agents, congestive heart failure, ocular hypertension | MERCK & CO., INC. (US) | 1992-03-31 | — | — | US | disclosed |
| WO-1991015209-A1 | SUBSTITUTED PYRIMIDINES, PYRIMIDINONES AND PYRIDOPYRIMIDINES | MERCK & CO., INC. (US) | 1991-10-17 | — | — | WO | disclosed |
| EP-0419048-A2 | Substituted pyrimidinones as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-03-27 | — | — | EP | disclosed |
| EP-0411766-A1 | Substituted quinazolinones as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-02-06 | — | — | EP | disclosed |
| CN-1048546-A | Substituted imidazo-fused 6 unit heterocycle as angiotensin II antagonism medicine | MERCK & CO INC (US) | 1991-01-16 | — | — | CN | disclosed |
| EP-0400974-A2 | Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists | MERCK & CO. INC. (US) | 1990-12-05 | — | — | EP | disclosed |
| EP-0400835-A1 | Substituted benzimidazoles as angiotensin II antagonists | MERCK & CO. INC. (US) | 1990-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034128-A1 | BCL-XL INHIBITORS | BCL2, BCL2L1, BCL2L10 | PTPN2 601/4885PTPN1 649/4885PTPRF 224/4885 |
| US-20260130925-A1 | METHODS FOR TREATING CANCER | PIK3R1, PIK3R5, PIK3R2 | PTPN2 869/4885PTPN1 846/4885PTPRF 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.